IONIQ’s breast cancer feasibility results published by IEEE
Salt Lake City, UT, November 30, 2021 – In collaboration with two of our Scientific Advisors, IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is proud to announce the prestigious IEEE Access peer-reviewed journal has published a scientific manuscript on the life-saving potential of our ‘breakthrough’ bioimpedance technology in breast cancer.
To read about our IONIQ System’s feasibility work in breast cancer and learn how it could be used alongside mammography to improve today’s standard of care, click here for the press release from the University of Utah and click here for the IEEE Access paper.
The lead author is Dr. Benjamin Sanchez. He heads the bioimpedance laboratory at the University of Utah School of Engineering and is one of our Scientific Advisors. Dr. Sanchez is an award-winning luminary in the field of electrical bioimpedance and computational electromagnetics with nearly 60 publications to his credit while at Harvard Medical School’s Department of Neurology, KTH-Royal Institute of Technology, Vrije Universiteit Brussel and Universitat Politecnica de Catalunya.
“The likelihood of success at fighting the cancer depends on when you act on it. If you can detect it and treat a person sooner, your chances of survival are higher,” Dr. Sanchez said.
Jared Bauer, IONIQ CEO, stated, ”We are incredibly proud and humbled by the body of work that Dr. Sanchez has contributed to the field of bioimpedance. This scientific manuscript is another spotlight on the life-saving potential of bioimpedance and our IONIQ System. We are fortunate to collaborate with world-renowned Scientific Advisors, like Dr. Sanchez. Together we can modernize early-stage cancer detection.”
** Read article in Salt Lake Tribune: https://www.sltrib.com/news/2021/12/19/new-technology-could-help/
** Read article in Diagnostics Word: https://www.diagnosticsworldnews.com/news/2022/01/13/bioimpedance-test-for-breast-cancer-could-hit-the-market-in-2023
About IONIQ Sciences, Inc.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA.
For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-736-0729 | acr@IONIQsciences.com
IONIQ Sciences, Vice President of Business Development
IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103